Search results
Results from the WOW.Com Content Network
This page was last edited on 3 February 2025, at 20:23 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The Division of Select Agents and Toxins (DSAT) of the Centers for Disease Control and Prevention is responsible for the Select Agent Program and the Etiologic Agent Import Permit Program. They inspect the laboratories of more than 300 organizations approved to use and transfer select agents , and put regulations in place to minimize risk in ...
The CDC has regulated the laboratories which may possess, use, or transfer select agents within the United States under the SAP since 2001. The SAP was established to satisfy requirements of the USA PATRIOT Act of 2001 and the Public Health Security and Bioterrorism Preparedness and Response Act of 2002, which were enacted in the wake of the September 11, 2001 attacks and the subsequent 2001 ...
In 2013, it provided necessary data, which addressed 10 specific biological agent knowledge gaps, to improve hazard, risk, and threat assessments. The data allowed for significant growth in the credibility of hazard and risk assessment modeling of bioterrorism scenarios for a variety of toxin threat agents, including both bacteria and viruses.
Crown Bioscience is a company that offers a range of preclinical and translational drug research and development platforms and services. These include in vivo, in vitro, ex vivo, in silico, patient derived xenograft (PDX), cell line derived xenograft (CDX), organoids and 3D models, oncology databases, biomarker, bioanalysis and bioinformatics services, as well as a biobank of liquid and human ...
Ambit was an American pharmaceutical company focused on development of kinase inhibitor therapeutics to treat a variety of human diseases. [ 1 ] : 3 [ n 1 ] As of March 2014 [update] , the company was based in San Diego , California, and consisted of a single facility.
Emergent BioSolutions was founded on September 5, 1998, by Fuad El-Hibri, under the name BioPort, which had formerly operated as a state-owned entity named Michigan Biological Products Institute [4] and was privatized as Emergent BioSolutions in 2004.
BioLegend is a global developer and manufacturer of antibodies and reagents used in biomedical research located in San Diego, California. [1] It was incorporated in June 2002 and has since expanded to include BioLegend Japan KK, where it is partnered with Tomy Digital Biology Co., Ltd. in Tokyo, BioLegend Europe in the United Kingdom, BioLegend GmbH in Germany, and BioLegend UK Ltd in the ...